According to Arrowhead Pharmaceuticals
's latest financial reports the company has $0.22 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-09-30 | $0.40 B | 7.23% |
2022-09-30 | $0.37 B | 2.34% |
2021-09-30 | $0.36 B | 16.58% |
2020-09-30 | $0.31 B | 21.95% |
2019-09-30 | $0.25 B | 238.03% |
2018-09-30 | $76.53 M | 16.65% |
2017-09-30 | $65.6 M | -23.15% |
2016-09-30 | $85.36 M | -13.56% |
2015-09-30 | $98.75 M | -35.94% |
2014-09-30 | $0.15 B | 447.75% |
2013-09-30 | $28.14 M | 707.88% |
2012-09-30 | $3.48 M | -57.21% |
2011-09-30 | $8.14 M | 18.91% |
2010-09-30 | $6.84 M | 238.93% |
2009-09-30 | $2.02 M | -79.99% |
2008-09-30 | $10.09 M | -58.15% |
2007-09-30 | $24.12 M | -13.92% |
2006-09-30 | $28.02 M | 24.29% |
2005-09-30 | $22.54 M | 149.36% |
2004-09-30 | $9.04 M | 567.06% |
2003-09-30 | $1.35 M | 7229.45% |
2002-09-30 | $0.01 M | 6723.25% |
2001-09-30 | $0 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $22.92 B | 10,308.16% | ๐บ๐ธ USA |
Moderna
MRNA | $8.60 B | 3,805.96% | ๐บ๐ธ USA |
Ligand Pharmaceuticals LGND | $0.17 B | -22.68% | ๐บ๐ธ USA |
Dicerna Pharmaceuticals DRNA | N/A | N/A | ๐บ๐ธ USA |
Alnylam Pharmaceuticals
ALNY | $2.43 B | 1,007.40% | ๐บ๐ธ USA |
Inovio Pharmaceuticals INO | $0.14 B | -34.04% | ๐บ๐ธ USA |